# US 2008/0305148 A1 · Treatment of spinal injuries using human umbilical mesenchymal stem cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0305148 A1
- Document ID: US20080305148A1
- Status: Published application
- Kind: A1
- Application number: 12/047,417
- Filed: 2008-03-13
- Published: 2008-12-11
- Earliest claimed: 2007-03-19
- Assignees: National Yang-Ming University
- Inventors: Yu-Show Fu
- Web page: https://patentgrep.com/patent/US20080305148A1

## CPC

- A61L 27/3878: {Nerve tissue, brain, spinal cord, nerves, dura mater}
- A61K 35/51: Umbilical cord; Umbilical cord blood; Umbilical stem cells
- A61L 24/0005: {Ingredients of undetermined constitution or reaction products thereof}
- A61L 24/106: {Fibrin; Fibrinogen}
- A61L 27/225: {Fibrin; Fibrinogen}
- A61L 27/3834: {Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells}
- A61P 25/00: Drugs for disorders of the nervous system
- A61L 2430/38: for reconstruction of the spine, vertebrae or intervertebral discs
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Transplantation of human umbilical mesenchymal stem cells (HUMSCs) to an area of a spinal injury is therapeutically effective in treating the spinal injury. Methods for treating spinal injuries based on such transplantation are described.

## Claims

### Claim 1

A method for treating a spinal injury in a subject comprising delivering an effective amount of human umbilical mesenchymal stem cells (HUMSCs) to an area of the spinal injury.

### Claim 2 (depends on 1)

The method of claim 1, wherein the HUMSCs are obtained from Wharton's Jelly.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the HUMSCs are delivered by direct injection into the area of the spinal injury.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the HUMSCs are delivered to the area of the spinal injury together with a fibrin glue.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the fibrin glue comprises about 10 mg/ml to about 1000 mg/ml fibrinogen, about 10 KIU/ml to about 500 KIU/ml aprotinin; and about 1 mM to about 100 mM calcium.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the fibrin glue comprises about 100 mg/m fibrinogen, about 200 KIU/ml aprotinin and about 8 mM calcium chloride.

### Claim 7 (depends on 4)

The method according to claim 4, wherein the HUMSCs are delivered before, simultaneously or after the delivery of the fibrin glue to the area of the spinal injury.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the HUMSCs are delivered in a hollow conduit filled with the HUMSCs.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the hollow conduit bridges a gap between severed ends of a transected spinal cord.

### Claim 10 (depends on 8)

The method according to claim 8, wherein the hollow conduit comprises a biodegradable polymeric material selected from the group consisting of collagen, poly(lactic acid) (PLA), poly(glycolic acid) (PGA), poly(lactic-co-glycolic acid) (PLGA), polycaprolactone, poly(caprolactone-co-lactic acid) (PCLA), chitosan, alginate, hyaluronic acid, gelatin, and fibrin.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the HUMSCs are delivered in combination with at least one additional treatment.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the at least one additional treatment is selected from the group consisting of methylprednisolone treatment, chondroitinase treatment, transplantation of another stem cell, Schwann cells bridge (SCs bridge), olfactory ensheathing glia and a combination thereof.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the effective amount of HUMSCs is about 104 to about 107 cells per administration.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the spinal injury is a complete injury.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the complete injury is a transection of the spinal cord.

### Claim 16 (depends on 1)

The method according to claim 1, wherein the spinal injury is an incomplete injury.

### Claim 17 (depends on 1)

The method according to claim 1, wherein the HUMSCs are delivered before, simultaneously or after the spinal injury.
